Related Experiment Videos
Gene therapy for hypertension: the preclinical data.
1Department of Physiology, College of Medicine, University of Florida, Gainesville, FL, USA. MIP@phys.med.ufl.edu
Hypertension (Dallas, Tex. : 1979)
|September 22, 2001
Summary
Gene therapy offers a promising approach for treating hypertension by targeting specific genes. Preclinical studies show that gene therapy, particularly using antisense oligodeoxynucleotides, can effectively lower blood pressure for extended periods.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Pharmacology
Background:
- Current hypertension treatments have limitations including short duration of action, side effects, and lack of specificity.
- Gene therapy presents a potential alternative for long-lasting and specific hypertension control.
Purpose of the Study:
- To review preclinical gene therapy approaches for hypertension treatment.
- To evaluate the efficacy and duration of blood pressure reduction using gene transfer and antisense strategies.
Main Methods:
- Gene transfer of vasodilator proteins (kallikrein, atrial natriuretic peptide, adrenomedullin, endothelin NO synthase) in rat models.
- Antisense approaches targeting genes like angiotensinogen and angiotensin type 1 (AT(1)) receptor using oligodeoxynucleotides or viral vectors.
Main Results:
- Gene transfer lowered blood pressure for 3 to 12 weeks.
- Antisense strategies demonstrated blood pressure reduction lasting days to months.
- Systemic delivery of antisense to AT(1) receptors reduced hypertension for up to 6 months in rodents.
Conclusions:
- Preclinical data supports the potential of gene therapy for hypertension.
- Antisense oligodeoxynucleotides show promise for clinical trials.
- Further research is needed for viral vector delivery methods.